Skip to content
2000
Volume 20, Issue 4
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

Background

Gliomas account for 30% of primary brain tumors in adults, and despite the scientific progress in the field, recurrence is prevalent. Glioma Stem Cells (GSCs) can generate tumor cells and and they are associated with treatment resistance, tumor progression, and recurrence. Furthermore, the expression of SOX transcription factors (SOX1, SOX2, SOX9) in these cells is responsible for maintaining an oncogenic genotype and is associated with an aggressive tumor phenotype. The relationship between SOX transcription factors and their prognostic role in recurrent gliomas has not been described in detail. Therefore, we set out to describe the relationship between SOX expression and Progression-free Survival (PFS) and Overall Survival (OS) in patients with recurrent gliomas.

Methods

In this observational study, we have retrospectively analyzed 69 patients, of which 20 met the inclusion criteria. The clinical, radiological, and histopathological findings have been described, and survival analysis has been performed according to SOX expression for PFS and OS.

Results

We found SOX1, SOX2, and SOX9 to show a non-statistically significant trend with increasing histopathological grade, co-expressed with Ki67, a cell proliferation factor.

Conclusion

There has been found an inversely proportional correlation between the degree of immunopositivity of SOX1 and OS. A higher SOX1 immunopositivity could predict a worse clinical prognosis. There has also been found an interaction between a pluripotent genotype (GSC) and cell proliferation.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928277672240429065526
2025-05-09
2025-12-26

  • From This Site

    /content/journals/pra/10.2174/0115748928277672240429065526
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. JacksonE.L. Alvarez-BuyllaA. Characterization of adult neural stem cells and their relation to brain tumors.Cell. Tiss. Org.20081881-221222410.1159/00011454118223308
     [Google Scholar]
  2. SongW-S. YangY-P. HuangC-S. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cellsJ Chin Med Assoc2016791053854510.1016/j.jcma.2016.03.01027530866
     [Google Scholar]
  3. AvilionA.A. NicolisS.K. PevnyL.H. PerezL. VivianN. Lovell-BadgeR. Multipotent cell lineages in early mouse development depend on SOX2 function.Genes Dev.200317112614010.1101/gad.22450312514105
     [Google Scholar]
  4. PevnyL. PlaczekM. SOX genes and neural progenitor identity.Curr. Opin. Neurobiol.200515171310.1016/j.conb.2005.01.01615721738
     [Google Scholar]
  5. ZhaoS. NicholsJ. SmithA.G. LiM. SoxB transcription factors specify neuroectodermal lineage choice in ES cells.Mol. Cell. Neurosci.200427333234210.1016/j.mcn.2004.08.00215519247
     [Google Scholar]
  6. Garros-RegulezL. GarciaI. Carrasco-GarciaE. Targeting SOX2 as a therapeutic strategy in glioblastoma.Front Oncol2016622210.3389/fonc.2016.0022227822457
     [Google Scholar]
  7. GarciaI. AldaregiaJ. Marjanovic VicenticJ. AldazP. Moreno-CugnonL. Torres-BayonaS. Oncogenic activity of SOX1 in glioblastoma.Sci Rep201774657510.1038/srep4657528425506
     [Google Scholar]
  8. DehcordiS.R. RicciA. Di VitantonioH. Stemness marker detection in the periphery of glioblastoma and ability of glioblastoma to generate glioma stem cells: clinical correlationsWorld Neurosurg201710589590510.1016/j.wneu.2017.05.09928559081
     [Google Scholar]
  9. MiconiG. PalumboP. DehcordiS.R. Immunophenotypic characterization of human glioblastoma stem cells: correlation with clinical outcomeJ Cell Biochem2015116586487610.1002/jcb.2504325559650
     [Google Scholar]
  10. ChewL-J GalloV The Yin and yang of Sox proteins: activation and repression in development and disease.J Neurosci Res200987153277328710.1002/jnr.2212819437544
     [Google Scholar]
  11. MaY.H. MentleinR. KnerlichF. KruseM.L. MehdornH.M. Held-FeindtJ. Expression of stem cell markers in human astrocytomas of different WHO grades.J. Neurooncol.2008861314510.1007/s11060‑007‑9439‑717611714
     [Google Scholar]
  12. WangL. HeS. YuanJ. MaoX. CaoY. ZongJ. TuY. ZhangY. Oncogenic role of SOX9 expression in human malignant gliomaMed Oncol20122953484349010.1007/s12032‑012‑0267‑z22714060
     [Google Scholar]
  13. RochaAMA de la SampronN AlonsoMM MatheuA Role of SOX family of transcription factors in central nervous system tumors.Am J Cancer Res20144431232425057435
     [Google Scholar]
  14. WenP Y MacdonaldD R ReardonD A Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupJ Clin Oncol201028111963197210.1200/JCO.2009.26.354120231676
     [Google Scholar]
  15. ChangS M ParneyI F HuangW Patterns of care for adults with newly diagnosed malignant gliomaJAMA2005293555756410.1001/jama.293.5.55715687310
     [Google Scholar]
  16. ReussD E MamatjanY SchrimpfD IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHOActa Neuropathol2015129686787310.1007/s00401‑015‑1438‑825962792
     [Google Scholar]
  17. NobusawaS. WatanabeT. KleihuesP. OhgakiH. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.Clin. Cancer Res.200915196002600710.1158/1078‑0432.CCR‑09‑071519755387
     [Google Scholar]
  18. LouisD.N. OhgakiH. WiestlerO.D. CaveneeW.K. BurgerP.C. JouvetA. ScheithauerB.W. KleihuesP. The 2007 WHO classification of tumours of the central nervous systemActa Neuropathol200711429710910.1007/s00401‑007‑0243‑417618441
     [Google Scholar]
  19. WegnerM. All purpose Sox: The many roles of Sox proteins in gene expression.Int. J. Biochem. Cell Biol.201042338139010.1016/j.biocel.2009.07.00619631281
     [Google Scholar]
  20. FangX. YoonJ-G. LiL. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysisBMC Genomics2011121110.1186/1471‑2164‑12‑1121211035
     [Google Scholar]
/content/journals/pra/10.2174/0115748928277672240429065526
Loading
Stem Cell Markers in Neoplasms and their Relationship with Progression-free and Overall Survival in Patients with Recurrence
Recent Patents on Anti-Cancer Drug Discovery 20, 548 (2025); https://doi.org/10.2174/0115748928277672240429065526
/content/journals/pra/10.2174/0115748928277672240429065526
/content/journals/pra/10.2174/0115748928277672240429065526
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): glioma stem cells; Gliomas; Ki67; SOX1; SOX2; SOX3; SOX9

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test